Charles River Laboratories International, Inc. $CRL Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp lessened its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 995,387 shares of the medical research company’s stock after selling 6,662 shares during the quarter. Mackenzie Financial Corp’s holdings in Charles River Laboratories International were worth $155,738,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Rothschild Investment LLC lifted its holdings in shares of Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after purchasing an additional 84 shares during the period. Neo Ivy Capital Management acquired a new position in Charles River Laboratories International in the 2nd quarter worth approximately $29,000. Atlantic Union Bankshares Corp acquired a new position in Charles River Laboratories International in the 3rd quarter worth approximately $31,000. Geneos Wealth Management Inc. raised its position in Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares during the last quarter. Finally, Allworth Financial LP lifted its stake in Charles River Laboratories International by 172.7% during the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 190 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. UBS Group upped their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, January 21st. JPMorgan Chase & Co. boosted their target price on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. TD Cowen lowered their price target on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Finally, Argus set a $200.00 price target on Charles River Laboratories International in a research report on Monday, November 17th. Ten research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $203.57.

Charles River Laboratories International Trading Up 0.9%

Charles River Laboratories International stock opened at $168.88 on Thursday. The firm has a market cap of $8.31 billion, a PE ratio of -57.05, a P/E/G ratio of 2.86 and a beta of 1.64. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88. The stock’s 50 day simple moving average is $193.48 and its two-hundred day simple moving average is $181.14. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The firm had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. During the same period in the previous year, the firm earned $2.66 EPS. The business’s quarterly revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.